Cargando…
Efficacy of PP121 in primary and metastatic non‑small cell lung cancers
Tyrosine kinase inhibitors are a clinically standard treatment option for non-small cell lung cancers (NSCLCs), the leading cause of cancer-related deaths in the US. These targeted agents include first, second and third generation tyrosine kinase inhibitors; however, these lack clinical efficacy in...
Autor principal: | Quick, Quincy A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011948/ https://www.ncbi.nlm.nih.gov/pubmed/36926188 http://dx.doi.org/10.3892/br.2023.1611 |
Ejemplares similares
-
Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review
por: Khwaja, Raida M., et al.
Publicado: (2022) -
Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016) -
Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer
por: Wei, Bing, et al.
Publicado: (2014) -
Half-lives of $^{121}$Cs and $^{121}$In isomers
por: Scheidemann, Ø, et al.
Publicado: (1974) -
Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer
por: Chen, Bing, et al.
Publicado: (2022)